Background: The reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) is an attractive target for the development of drugs used in the treatment of HIV-1 infection and acquired immune deficiency syndrome (AIDS). We have continued the search for novel anti-HIV-1 agents using the structure-activity relationships of the successful 1,3disubstituted and 1,3,6-trisubstituted uracil-type HIV-1 RT inhibitors. Methods: A series of new triazine analogs were synthesized using an established method. The anti-HIV-1 activities of these compounds were determined based on the inhibition of virus-induced cytopathogenicity in MT-4 cells. The cytotoxicity of the compounds was evaluated by assessing the viability of mock-infected cells. Results: Some of the compounds showed good-to-moderate activities against HIV-1, with half-maximal effective concentrations (EC 50 ) in the submicromolar range. In particular, a dihydro-1-(4-aminobenzyl)triazine analog showed satisfactory anti-HIV-1 activity with an EC 50 of 0.110 mM and a selectivity index (SI) of 909. Furthermore, molecular modeling analyses were performed to explore the major interactions between HIV-1 RT and potent inhibitors. These results may be important for further development of this class of compounds as anti-HIV-1 agents. Conclusion: The satisfactory anti-HIV-1 activity of triazine analogs may serve as the basis for further investigations of the behavior of this class of compounds against drug-resistant mutants.
Introduction
The reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) is an attractive target for the development of drugs used in HIV-1 infection and AIDS treatment. It is a multifunctional enzyme that is crucial to viral replication. Currently, two functionally distinct classes of HIV-1 RT inhibitors (nucleoside and non-nucleoside) have been discovered and are used clinically. In particular, non-nucleoside RT inhibitors (NNRTIs), with a wide range of chemically diverse structures, have gained an important place in clinical use given their unique antiviral potency, generally low toxicity, and favorable pharmacokinetic properties. [1] [2] [3] Among the more than 50 different series of NNRTIs reported hitherto, 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT, Figure 1 ), which possesses a uracil skeleton, 4, 5 was the first compound shown to target HIV-1 RT specifically. Since HEPT discovery, related uracil derivatives have been synthesized. In particular, emivirine (Figure 1 ), [6] [7] [8] [9] formerly known as MKC-442, was chosen as a candidate for clinical trials in AIDS patients, and is the best-known HEPT derivative. It also possesses an uracil skeleton. However, the phase III study was halted when emivirine was found to activate the liver enzyme cytochrome P450, which metabolizes protease inhibitors. 10 We also continued the search for an anti-HIV-1 agent using the structure-activity relationships of the 1,3-disubstituted and 1,3,6-trisubstituted uracils. [11] [12] [13] [14] [15] [16] We have demonstrated that the 3,5-dimethylbenzyl group at the N 3 -position and the amino group at the C6-position of the uracil skeleton play an important role in enhancing the anti-HIV-1 activity. Notably, substitution at the 1-position (with a benzyl or 4-picolyl group) of 6-amino-3-(3,5-dimethylbenzyl)uracil to obtain 1a-b (Table 1 ) yielded satisfactory anti-HIV-1 activity, with EC 50 values of 0.07 AE 0.01 mM and 0.03 AE 0.03 mM, respectively. 14, 15 Furthermore, N 1 -4aminobenzyl-C6-aminouracil derivatives (1c, Table 1 ) exhibited superior activities, with EC 50 values of 0.010 AE 0.006 mM. 16 In an ongoing effort to discover potential NNRTIs with high anti-HIV-1 activity and low cytotoxicity, we designed 22 structurally relevant, novel classes of 1-substituted 3-(3,5-dimethylbenzyl)triazine analogs (3a-c, 4a-p, and 5, Table 2 ), and 3-(4-fluorobenzyl)-1-(4methoxybenzyl)triazine derivatives (6a-b, Table 2 ) by replacing the uracil skeleton with a triazine moiety, by means of using the biological isostere principle, [17] [18] [19] as shown in Figure 2 . Moreover, it has been confirmed that emivirine bound to HIV-1 RT at the nevirapinebinding site in the X-ray co-crystal structure; 20 thus, preliminary structure-activity relationship studies and molecular modeling analyses using two types of prospective ligands (4c and 5, Table 2 ) were also performed to explore the major interactions between the nevirapine-binding site in HIV-1 RT and 4c or 5. Table 2 ), and its 6-hydroxy counterpart (6b, Table 2) were synthesized according to previous reports based on Balboni's procedure. 21, 22 The 1-substituted 6-methylthiotriazine derivatives (3) and 1-substituted 6aminotriazine analogs (4) were essentially synthesized by alkylation at the 1-position of the triazine skeleton of the intermediate (2), using our previously reported method, as shown in Scheme 1. [14] [15] [16] First, compound (2) was allowed to react with the appropriate alkyl halides (e.g. 4-nitrobenzyl bromide, 4-picolyl chloride, or 4-fluorobenzyl bromide) to yield the corresponding 1-alkylated products (3), 35-98% of which was treated with methanolic ammonia to give the 6-aminated products (4) in 30-92% yields. 1-(4-Aminobenzyl)-substituted triazine derivatives (3c, 4c, and 5) were synthesized from the 1-(4-nitrobenzyl)-substituted triazine analog 3h. Reduction of 3h with NaBH 4 and NiCl 2 Á6H 2 O in the presence of MeOH and THF at 0 C afforded the 1-(4-aminobenzyl)-6methylthiolated triazine analog 3c and dihydro-1-(4aminobenzyl)triazine derivative 5 at 35% and 53%, respectively. 23 The C6-amination of 3c with methanolic ammonia gave 4c.
Methods

Chemistry
3-(3,5-Dimethylbenzyl)-6-methylthio-1,3,5-triazine- 2,4(1H,3H)-dione (2), 6-amino-3-(4-fluorobenzyl)-1-(4- methoxybenzyl)-1,3,5-triazine-2,4(1H,3H)-dione (6a,
Anti-HIV-1 assay
MT-4 cells were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL of penicillin G, and 100 mg/mL of streptomycin. The III B strain of HIV-1 was used throughout the experiment. The virus was propagated and titrated in MT-4 cells. Virus stocks were stored at À80 C until use. The anti-HIV-1 activity of the test compounds was determined by the inhibition of virusinduced cytopathogenicity in MT-4 cells. 24 Briefly, MT-4 cells (1 Â 10 5 cells/mL) were infected with HIV-1 at a multiplicity of infection (MOI) of 0.1 and were cultured in the presence of various concentrations of the test compounds. After four-day incubation at 37 C in 5% CO 2 , the number of viable cells was monitored by the water-soluble tetrazolium dye MTT. The cytotoxicity of the compounds was evaluated in parallel with their antiviral activity, based on the viability of mockinfected cells, as determined by the MTT method.
Materials Instrumentation 1 H NMR and 13 C NMR spectra were taken with an Ultrashield TM 400 Plus FT NMR System (BRUKER, Germany). Chemical shifts and coupling constants (J) were given in d and Hz, respectively. Melting points were determined on a Yanaco MP-500D. Highresolution mass spectrometry was performed on an APEX IV mass spectrometer (BRUKER) with electrospray ionization mass spectroscopy (ESI-MS).
Compounds
General procedure for the synthesis of 3
A solution of compound 2 (41.6 mg, 0.15 mmol), appropriate alkyl halide (0.23 mmol) and K 2 CO 3 (24.9 mg, 0.18 mmol), in dry DMF (0.25 mL) was stirred at room temperature. After 3-21 h stirring, the mixture was extracted with acetic-acid-ethylester (AcOEt). The organic extracts were washed with water and saturated sodium chloride solution, dried with sodium sulfate, and then evaporated. The residue was purified by silica gel column chromatography to afford 3. 13 13 Dihydro-1-(4-aminobenzyl)-3-(3,5-dimethylbenzyl)-1,3,5-triazine-2,4(1H,3H)-dione (5) . Compound 3h (0.085 g, 0.21 mmol) was dissolved in the 3:1 mixture of dry MeOH (3.0 mL) and dry THF (1.0 mL), and NaBH 4 (0.033 g, 1.00 mmol) and NiCl 2 Á 6H 2 O (0.08 g, 0.32 mmol) were added to the solution, which was stirred for 30 min at 0 C. The mixture was extracted with AcOEt, washed with saturated aqueous sodium chloride solution, dried with sodium sulfate, and then evaporated. The residue was purified by silica gel column chromatography (AcOEt) to give compound 3c (0.028 g, 0.07 mmol, 35%, the structural assignment was described above) and 5 (0.038 g, 0.11 mmol, 53%), respectively. 
Results
Biological activity
The antiviral activities of the 6-methylthio (3a-c), 6amino (4a-p), and dihydro (5) derivatives of 1-substituted-3-(3,5-dimethylbenzyl)triazine and 6-amino (6a) and 6-hydroxy (6b) analogs of 1-(4-methoxybenzyl)-3-(4-fluorobenzyl)triazine were determined by examining the inhibitory effects of these compounds on HIV-1induced cytopathogenicity and cell viability in MT-4 cells. The cytotoxicity of these compounds, which were dissolved in dimethyl sulfoxide at concentrations up to 100 mM, was evaluated based on the viability of mockinfected cells, as determined by the MTT method. Some of the compounds in the series of 6-amino derivatives of 1-benzylated-3-(3,5-dimethylbenzyl)triazine (4a-k) exhibited good-to-moderate anti-HIV-1 activity with EC 50 values ranging from 0.068 mM to 3.7 mM, except for the 1-(2,6-difluorobenzyl)triazine derivative 4g, which had an EC 50 value of 38 AE 18 mM (Table 2) . Among these compounds, the 6-amino derivative of N 1 -(4-aminobenzyl)triazine 4c showed satisfactory anti-HIV-1 activity, with an EC 50 value of 0.068 AE 0.030 mM, and exhibited moderate values of CC 50 (47 AE 7 mM) and selectivity index (SI) (691). The introduction of the pamino group of the benzyl skeleton at the N 1 position in triazine increased the activity of the compounds compared to the activity of the unsubstituted compound 4a (EC 50 ¼ 0.19 AE 0.02 mM). A similar result was obtained for the N 1 -(4-aminobenzyl)uracil analog 1c
(EC 50 ¼ 0.010 AE 0.006 mM), compared to the unsubstituted compound 1a (EC 50 ¼ 0.07 AE 0.01 mM) ( Table 1) . 16 In contrast, three types of 6-methylthiolated derivatives (3a-c) exhibited considerably less anti-HIV-1 activity than their 6-amino counterparts (4a-c); for example, 3a (N 1 -benzyl-6-methylthiotriazine) was approximately 16 times less potent (EC 50 ¼ 3.0 AE 1.0 mM, SI ¼ 15) than its N 1 -benzyl-6-aminotriazine analog, 4a (EC 50 ¼ 0.19 AE 0.02 mM, SI > 526). The 6-(4-picolyl), 6-(2-picolyl), and 6-(3-picolyl) derivatives 4l-n showed moderate anti-HIV-1 activity with EC 50 values from 0.34 mM to 1.2 mM.
Additionally, the dihydro-N 1 -4-aminobenzyltriazine analog 5, in which the 6-methylthio group of the triazine system of 3c was removed and hydrogenated, showed not only comparable anti-HIV-1 activity (EC 50 ¼ 0.11 AE 0.05 mM) but also low cytotoxicity with CC 50 and SI values of > 100 mM and > 909, respectively.
Unfortunately, the 6-(cyanomethyl) and 6-(ethylphenyl) analogs (4o-p) and the 6-amino or 6-hydroxy derivatives of N 3 -(4-fluorobenzyl)-N 1 -(4-methoxy benzyl)triazine (6a-b) hardly demonstrated anti-HIV-1 activity, indicating that the N 1 -benzyl or picolyl skeleton as well as the N 3 -3,5-dimethylbenzyl system plays an important role in the anti-HIV-1 activity of the triazine series.
Discussion
Molecular modeling analysis
The X-ray co-crystal structure (PDB: 1VRT) of HIV-1 RT with bound nevirapine was taken from PDB 2 for use in docking studies. A docking model comprising ligand 4c or 5, which showed the most promising anti-HIV-1 activity, bound to HIV-1 RT, was constructed by a conformational search using MacroModel (ver. 9.1). AMBER* was used as the force field, and more than 3000 conformers of the corresponding ligands were optimized. Figure 3 (a) and (b) shows the molecular docking of 4c and 5, respectively, in the allosteric site of HIV-1 RT. This docking structure was found to be significantly different from that of the nevirapine-binding site in the HIV-1-emivirine complex. 20 The 6-amino group of 4c is hydrogen bonded to the amide group of the Lys101 residue (NH . . . O ¼ C), while the 6-methylen moiety of the reduced triazine analog 5 is not hydrogen bonded to the Lys101 residue. Moreover, the 3,5-dimethylbenzyl moiety of 4c or 5, which was oriented around the hydrophobic area, enhanced the p-p stacking of the benzene rings of the Tyr181 and Tyr188 residues. A CH-p interaction was observed between the methyl group of the 3,5-dimethylbenzyl moiety and the indole skeleton of the Trp229 residue, or between the benzene rings of the 3,5-dimethylbenzyl moiety and the isobutyl groups of the Leu234 residue. In particular, the result of this calculation of HIV-1 RT with bound 4c was almost the same as that for N 1 -benzyluracil (1a), N 1 -4-picolyluracil (1b), or N 1 -4-aminobenzyluracil (1c). 15, 16 As to the comparison of the triazine ring with an uracil skeleton for anti-HIV-1 activity, for instance, triazine analog 4a was less potent (EC 50 ¼ 0.19 AE 0.02 mM, Table 2 ) than the uracil counterpart 1c (0.07 AE 0.01 mM, Table 1 ), suggesting that nitrogen atom at the N 5 position of triazine ring might contribute to the decrease in the anti-HIV-1 activity. Figure 3 (c) shows the overlay of the docked conformations of the 6-amino analog 4c (cyan) and dihydro-triazine derivative 5 (gray) bound to HIV-1 RT at the nevirapine-binding site, showing that the most stable conformations of 4c and 5 were substantially similar.
In conclusion, we designed 22 structurally relevant, novel classes of 1-substituted 3-(3,5-dimethyl benzyl)triazine analogs, and 3-(4-fluorobenzyl)-1-(4methoxybenzyl)triazine derivatives. The satisfactory anti-HIV-1 activity of triazine analogs may serve as the basis for further investigations of the behavior of this class of compounds against drug-resistant mutants.
